HSD17B13 and metabolic dysfunction-associated steatotic liver disease: They have been launched into phase I/II clinical trials for NAFLD, significantly downregulating the liver expression of HSD17B13 mRNA and protein, leading to marked reduction in transaminase levels (clinical trials: NCT04565717; NCT04202354) [30].